Alphabet (Google’s parent) has significantly ramped up research and development spending in recent years. In 2022, Google spent about $39.5 billion on R&D, which jumped to $45.4 billion in 2023. This ~15% increase was driven largely by higher personnel costs (adding thousands of engineers) and one-time charges like office space consolidation.
R&D now represents roughly 15% of Google’s annual revenue,
The introduction of the Chinese generative AI model has created a storm on Wall Street, and tall trees are the first to bear the brunt of it. Big tech names have shown weaknesses and AI-related stocks have faced issues as the fear of the new-gen AI model, DeepSeek, and circumstances surrounding its creation spread through the market.
Stanley Druckenmiller has an exemplary history and track record trading so we wanted to investigate whether any opportunities leap out in his current portfolio.
Which positions, if any, are underwater? And are there any diamonds in the rough now that are on sale?
In Druckenmiller’s Duquesne Family Office there are 75 stock positions as of September 30,
Billionaire Stanley Druckenmiller has been making large changes to his portfolio recently, leaving retail investors struggling to keep up with what the famous stock picker is thinking.
One of the smaller holdings in Druckenmiller’s portfolio that makes for interesting examination is ARS Pharmaceuticals (NASDAQ:SPRY).
Druckenmiller’s 536,900 shares of SPRY are currently valued at around $7 million.
» Read more about: 1 Under-the-Radar Pharma Stock with 90% Upside? »
CVS Health (NYSE:CVS) share price declined by over 23% over the past twelve months. Hurting shareholders was the recent leadership transition from CEO Karen Lynch to David Joyner, a shift that brought uncertainty to the company’s direction as investors questioned the company’s stability while facing ongoing challenges.
Few traders in history have the capacity to seamlessly transition across asset classes, zooming out to see the big macro picture and in to see the minutia of a company’s 10Q but Stan Druckenmiller ranks as one of the few who have succeeded in so doing.
Stan’s thesis has been that the Fed is really in a bind,
When CEO Elon Musk reported Tesla’s latest earnings results this week, few were excited by the numbers.
In fact, the share price immediately fell off a cliff in after-hours trading to $356 per share but within minutes a sharp bounce back occurred and, in the virtual blink of an eye, the share price was back over $400 per share.
Planet Labs combines satellite imaging and data analytics technologies to provide a service valuable to government agencies, corporations, and non-governmental organizations. The company has been developing its unique technology for 14 years, but it didn’t become a publicly traded company until 2021.
» Read more about: Nearly 200% Higher, Will This Space Stock Keep Soaring? »
Stanley Druckenmiller may be best known for his role with George Soros in shorting the British pound in 1992, which famously became known as breaking the Bank of England. That position resulted in a cumulative profit of over a billion dollars, and all while Druckenmiller was only in his late 30s.
At a time when many professional investors consider themselves in their early innings of their careers,
» Read more about: The Formula Behind Billionaire’s 30-Year Win Streak »
Billionaire Stanley Druckenmiller has been shaking up his portfolio lately, selling his entire stake in NVIDIA and most of his Palantir shares in order to diversify into more value-oriented stocks.
One of the most interesting buys Druckenmiller has made has been a 1.43 million share stake in Teva Pharmaceutical Industries (NYSE:TEVA).
» Read more about: Stanley’s Latest Bold Bet, Should You Follow? »
